AIMNEXT spun off from AIMMED in 2024 to specialize in the R&D and commercialization of Digital Therapeutics (DTx). We aim to improve healthcare outcomes by providing evidence-based, safe, effective, and equitable software interventions for patients. We plan to showcase our fertility improvement healthcare service at CES 2026.